Parabilis Medicines closed a $305 million Series F financing to advance its corkscrew-shaped peptide platform and lead candidate zolucatetide into late-stage testing. The round, one of the largest disclosed in early January, included RA Capital, Fidelity and Janus Henderson and increases the company’s runway for clinical expansion and potential regulatory filings. Parabilis said the financing supports plans to move toward registrational programs and indicated openness to a public offering; executives framed the fundraise as enabling multiple clinical shots on goal. The company highlighted preliminary efficacy in its Phase 1/2 data and the platform’s ability to access intracellular targets traditionally considered undruggable. The large private raise reinforces investor appetite for modality-innovative oncology assets and positions Parabilis to accelerate pivotal-stage development and potential partnering or IPO discussions.